Literature DB >> 9120282

Construction and characterization of human CD7-specific single-chain Fv immunotoxins.

M E Pauza1, S O Doumbia, C A Pennell.   

Abstract

To develop novel therapeutic agents for treatment of human T cell malignancies, we constructed two single-chain Fv (sFv) immunotoxins specific for the T cell-associated Ag CD7. The sFv fragments were derived from the murine hybridomas 3A1e and 3A1f and were expressed as soluble proteins in Escherichia coli. Surface plasmon resonance analyses demonstrated that the purified 3A1e and 3A1f sFv fragments specifically bound CD7 with high affinity, 8.1 and 1.8 nM, respectively. The difference in affinity is chiefly due to a slower dissociation rate for the 3A1f sFv fragment. Despite this difference, both monovalent sFv fragments were comparably internalized by CD7+ human T leukemic cells within 30 min. These data support findings of previous studies suggesting that CD7 internalization does not require cross-linking. The sFv immunotoxins were assembled by linking ricin toxin A chain to the C termini of the sFv fragments via disulfide bonds. Both sFv immunotoxins were comparably potent in their ability to inhibit protein synthesis in vitro in CD7+ Jurkat cells (50% inhibiting concentration = 15 pM). Further preclinical studies on the use of the 3A1e and 3A1f sFv immunotoxins to treat human T cell diseases therefore appear warranted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120282

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

Review 2.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.

Authors:  Jinle Tang; Jialu Li; Xuejun Zhu; Yuan Yu; Dan Chen; Lei Yuan; Zhenyang Gu; Xingding Zhang; Lin Qi; Zhishu Gong; Pengjun Jiang; Juhua Yu; Huimin Meng; Gangli An; Huyong Zheng; Lin Yang
Journal:  Oncotarget       Date:  2016-06-07

4.  Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody.

Authors:  Jing Ye; Yujie Jia; Israth Jahan Tuhin; Jingwen Tan; Masuma Akter Monty; Nan Xu; Liqing Kang; Minghao Li; Xiaoyan Lou; Meixia Zhou; Xiaoyan Fang; Jiaqi Shao; Hongjia Zhu; Zhiqiang Yan; Lei Yu
Journal:  Mol Ther Oncolytics       Date:  2022-02-20       Impact factor: 7.200

5.  Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.

Authors:  Yuan Yu; Jialu Li; Xuejun Zhu; Xiaowen Tang; Yangyi Bao; Xiang Sun; Yuhui Huang; Fang Tian; Xiaomei Liu; Lin Yang
Journal:  Int J Nanomedicine       Date:  2017-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.